Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a 4-year follow-up from the RESONATE-2 study Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, S., Dean, J. P., James, D. F., Kipps, T. P. KARGER. 2018: 29

View details for Web of Science ID 000446816500074